Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Sell rating on PepGen Inc.. The associated price target remains the same with $3.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tazeen Ahmad has given his Sell rating due to a combination of factors related to PepGen’s clinical and regulatory outlook. Early data from the 5 mg/kg cohort in the FREEDOM2 DM1 trial show only modest splicing correction versus placebo and limited functional gains, with no clear improvements on key motor endpoints that would strengthen confidence in the drug’s efficacy.
Moreover, the company’s lead program faces an ongoing partial U.S. clinical hold, with no visibility on when the FDA might clear higher-dose testing, while pivotal 10 mg/kg and 12.5 mg/kg readouts remain several years away. Safety concerns at higher doses linger given prior kidney-related adverse events in another program, and competing DM1 therapies have delivered more compelling functional data, all of which, in Ahmad’s view, justify a price objective below the current share price and support the Underperform (Sell) recommendation.
In another report released today, TipRanks – Anthropic also downgraded the stock to a Sell with a $4.50 price target.
PEPG’s price has also changed slightly for the past six months – from $4.620 to $4.230, which is a -8.44% drop .